Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia

Acute Myeloid Leukemia Clinical Trial

Official title:

Management of Venous Thromboembolic Events (VTE) in Patients With Hematologic Disorders and Treatment-Induced Thrombocytopenia: A Pilot Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03195010
• Other study ID #: 9799
• Secondary ID: NCI-2017-0086497
• Status: Terminated
• Phase: Phase 2
• Start date: June 9, 2017
• Est. completion date: December 21, 2018

Study information

• Verified date: October 2019
• Source: Fred Hutchinson Cancer Research Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot clinical trial compares the safety of two different platelet transfusion "thresholds" among patients with blood cancer or treatment-induced thrombocytopenia whose condition requires anticoagulant medication (blood thinners) for blood clots. Giving relatively fewer platelet transfusions may reduce the side effects of frequent platelet transfusions without leading to undue bleeding.

Description:

PRIMARY OBJECTIVES:

I. To determine feasibility of a randomized controlled trial comparing two different platelet transfusion thresholds (50 x 10^9/L versus [vs] 30 x 10^9/L) in patients with treatment or malignancy-induced thrombocytopenia requiring therapeutic anticoagulation.

SECONDARY OBJECTIVES:

I. Progressive or new venous thromboembolic (VTE).

II. Progressive or new arterial thromboembolism (ATE).

III. Hemorrhagic events (World Health Organization [WHO] grade 2 or greater).

IV. A composite of I, II and III.

V. Major bleeds (WHO grade 3 or 4).

VI. Number of platelet transfusions per patient during the study period.

VII. Platelet transfusion related complications (including transfusion reactions, alloimmunization and volume overload).

VIII. Degree to which platelet target thresholds are achieved.

OUTLINE: Patients are randomized into 1 of 2 groups.

GROUP I (Lower dose): Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to > 50 x 10^9 for 3 consecutive days in the absence of transfusions.

GROUP II (Higher dose): Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to > 50 x 10^9 for 3 consecutive days in the absence of transfusions.

After completion of study, patients are followed up at 30 days.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: December 21, 2018
• Est. primary completion date: December 21, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Any patient with non-acute promyelocytic leukemia (APL) acute leukemia (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], biphenotypic leukemia) undergoing curative intent chemotherapy OR any patient undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for a hematologic disorder (including acute leukemia as above, chronic myelogenous leukemia [CML], chronic lymphocytic leukemia [CLL], myelodysplastic syndrome [MDS], primary or secondary myelofibrosis, hypereosinophilic syndromes, plasma cell disorders, B-cell or T-cell lymphoma)

• Disease may be measurable or non-measurable

• Diagnosis of symptomatic venous thromboembolism requiring therapeutic-dose anticoagulation (unfractionated or low-molecular weight heparin or oral anticoagulants) throughout the period of hematopoietic recovery

• Anticipated platelet count =< 50 x 10^9/L for >= 5 days within 72 hours of enrollment

• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Separate episode of VTE or arterial thrombosis within 3 months of enrollment

• Major bleed (WHO grade 3 or 4) within 6 months of enrollment

• Active bleeding (grade 2 or higher) at the time of enrollment

• History of intracranial bleeding at any time

• Disorders of hemostasis including von Willebrand disease, hemophilia, platelet function disorders

• Concomitant use of aspirin or non-steroidal anti-inflammatory drugs

• Evidence of disseminated intravascular anticoagulation (DIC) as determined by the patient's primary provider

• History of alloimmunization (defined as platelet refractoriness with panel reactive antibody [PRA] > 25%) at the time of or prior to enrollment

• Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris

• Psychiatric illness/social situations that would limit compliance with study requirements

• Pregnant or able to become pregnant and unwilling to use two forms of birth control during the study period

Related Conditions & MeSH terms

• Acute Biphenotypic Leukemia
• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• B-Cell Non-Hodgkin Lymphoma
• Chronic Lymphocytic Leukemia
• Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Hematologic and Lymphocytic Disorder
• Hematologic Diseases
• Hematopoietic Cell Transplantation Recipient
• Leukemia
• Leukemia, Biphenotypic, Acute
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Non-Hodgkin
• Lymphoma, T-Cell
• Myelodysplastic Syndrome
• Myelodysplastic Syndromes
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Primary Myelofibrosis
• Secondary Myelofibrosis
• T-Cell Non-Hodgkin Lymphoma
• Thrombocytopenia
• Thromboembolism
• Venous Thromboembolism

Intervention

Biological:
• Platelet Transfusion
Undergo lower dose platelet transfusion
• Platelet Transfusion
Undergo higher dose platelet transfusion

Locations

Country	Name	City	State
United States	Fred Hutch/University of Washington Cancer Consortium	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Fred Hutchinson Cancer Research Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Eligible Patients Approached for the Study		Up to 1 year
Primary	Number of Patients Approached for But Refusing Consent	Reasons for ineligibility will be reported qualitatively in order to inform future studies.	Up to 1 year
Primary	Number of Patients Consenting to Enrollment		Up to 1 year
Primary	Number of Patients Eligible		Up to 1 year
Primary	Number of Patients Screened and Deemed Ineligible	Reasons for ineligibility will be reported qualitatively in order to inform future studies.	Up to 1 year
Primary	Number of Patients Successfully Following Protocol	Will evaluate the number of patients successfully following protocol, defined as receiving transfusions 'on protocol' at the end of the study period.	Up to 1 year
Secondary	Incidence of Hemorrhagic Events (World Health Organization Grade 2 or Greater)	Will evaluate the incidence of hemorrhagic events (World Health Organization grade 2 or greater).	Up to 1 year
Secondary	Major Bleeds (World Health Organization Grade 3 or 4)	Will evaluate the major bleeds (World Health Organization grade 3 or 4).	Up to 1 year
Secondary	Number of Platelet Transfusions Per Patient During the Study Period		Up to 1 year
Secondary	Percent of Days on Which Subjects Are Transfused (or Transfusion Are Not Given)	The frequency with which transfusions are given despite a platelet count above the determined threshold will be documented, as will the frequency with which transfusions are not administered within 24 hours after a platelet count below the determined threshold.	Up to 1 year
Secondary	Platelet Transfusion Related Complications	Total number of transfusion reactions, patients experiencing alloimmunization and volume overload will be reported.	Up to 1 year
Secondary	Progressive or New Arterial Thromboembolism	Will evaluate the progression or new arterial thromboembolism by either documented acute electrocardiographic changes compatible with myocardial injury and/or serum biochemical changes diagnostic of myocardial infarction, or documented imaging (computed tomography or magnetic resonance imaging) changes compatible with infarct due to embolism in the presence of a new neurological deficit, or imaging demonstrated intraluminal filling defects in an arterial distribution accompanied by symptoms of acute ischemia (acute onset pain, pallor, loss of pulses or other end-organ damage).	Up to 1 year
Secondary	Progressive or New Venous Thromboembolic	Will evaluate the progressive or new venous thromboembolic. Will require imaging confirmation, defined as intraluminal filling defect(s) on contrast-enhanced computed tomography or incompressible venous segment(s) on ultrasonography.	Up to 1 year